Capital City Trust Co. FL Sells 552 Shares of Johnson & Johnson (NYSE:JNJ)

Capital City Trust Co. FL decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,380 shares of the company’s stock after selling 552 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of Capital City Trust Co. FL’s investment portfolio, making the stock its 14th largest position. Capital City Trust Co. FL’s holdings in Johnson & Johnson were worth $6,704,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Christopher J. Hasenberg Inc acquired a new position in Johnson & Johnson during the first quarter worth about $31,000. Keener Financial Planning LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $40,000. WFA Asset Management Corp increased its stake in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $45,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE JNJ opened at $149.88 on Friday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The business has a 50-day simple moving average of $147.94 and a two-hundred day simple moving average of $153.50. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The company has a market cap of $360.71 billion, a P/E ratio of 9.34, a P/E/G ratio of 2.49 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.68 EPS. Research analysts anticipate that Johnson & Johnson will post 10.61 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price for the company. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, July 1st. Finally, Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.